Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 16/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 16/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9976590 | 0.95 | OPRM1 (0.50) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL20756941 | 0.94 | OPRM1 (0.43) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL22874788 | 0.93 | OPRM1 (0.49) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL824131 | 0.90 | OPRL1 (0.49) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL14519152 | 0.89 | OPRM1 (0.47) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL18664010 | 0.86 | OPRL1 (0.38) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL20756988 | 0.86 | OPRL1 (0.38) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL20756734 | 0.86 | OPRL1 (0.48) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL24585209 | 0.86 | OPRM1 (0.54) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL24267669 | 0.84 | OPRL1 (0.51) | OPRM1OPRL1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11718613-B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-08-08 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-18 | — | — | US | disclosed |
| WO-2023014908-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2023279041-A1 | INDAZOLE COMPOUNDS | TYRA BIOSCIENCES, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| EP-3242872-B1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2019-07-03 | — | — | EP | disclosed |
| WO-2018106643-A1 | HETEROCYCLIC AZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-14 | — | — | WO | disclosed |
| US-9802904-B2 | Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-10-31 | — | — | US | disclosed |
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | AR, CYP17A1, KLK3 | OPRM1 585/4885OPRL1 489/4885OPRK1 256/4885 |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | OPRM1 3619/4885OPRL1 4502/4885OPRK1 3829/4885 |
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | OPRM1 15/4885OPRL1 33/4885OPRK1 36/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | OPRM1 3619/4885OPRL1 4502/4885OPRK1 3829/4885 |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | OPRM1 4373/4885OPRL1 2927/4885OPRK1 2682/4885 |
| US-11718613-B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | BCL2A1, BCL3, BCL2 | OPRM1 4409/4885OPRL1 3714/4885OPRK1 4331/4885 |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | OPRM1 4448/4885OPRL1 4222/4885OPRK1 3341/4885 |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | CRBN, IKZF1, IKZF3 | OPRM1 4416/4885OPRL1 2677/4885OPRK1 2813/4885 |
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | IRAK4, FLT3, IRAK2 | OPRM1 4631/4885OPRL1 3843/4885OPRK1 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.